Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dabigatran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 19/20 | 1.00 |
| ▸ | NQO2 | P16083 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | F10 | P00742 | 1/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 1.00 |
| ▸ | PROC | P04070 | 1/20 | 1.00 |
| ▸ | HPN | P05981 | 1/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 1/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 1/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dabigatran SCHEMBL29582891 | 1.00 | F2 (1.00) | F2NQO2SLC22A2F10PLG | |
| Dabigatran SCHEMBL30038681 | 1.00 | F2 (1.00) | F2NQO2SLC22A2F10PLG | |
| Dabigatran SCHEMBL15152349 | 0.99 | F2 (0.98) | F2NQO2SLC22A2F10PLG | |
| Dabigatran SCHEMBL21768719 | 0.99 | F2 (0.98) | F2NQO2SLC22A2F10PLG | |
| Dabigatran SCHEMBL29045198 | 0.99 | F2 (0.98) | F2NQO2SLC22A2F10PLG | |
| Dabigatran SCHEMBL27982835 | 0.99 | F2 (0.98) | F2NQO2SLC22A2F10PLG | |
| Dabigatran SCHEMBL28535963 | 0.97 | F2 (0.94) | F2NQO2SLC22A2F10PLG | |
| Dabigatran SCHEMBL20211336 | 0.97 | F2 (0.94) | F2NQO2SLC22A2F10PLG | |
| Dabigatran SCHEMBL28722375 | 0.96 | F2 (0.93) | F2NQO2SLC22A2F10PLG | |
| Dabigatran SCHEMBL28341350 | 0.96 | F2 (0.93) | F2NQO2SLC22A2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16788 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098615-A1 | COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF IN PREPARATION OF DRUGS FOR TREATING CARDIOVASCULAR AND CEREBROVASCULAR DISEASES | 上海东西智荟生物医药有限公司 | 2026-05-15 | — | — | WO | claimed |
| EP-4313104-B1 | DC009 FOR TREATING ACUTE ISCHEMIC STROKE | LUMOSA THERAPEUTICS CO LTD (TW) | 2026-05-13 | — | — | EP | claimed |
| EP-4739305-A1 | BUDIODARONE FOR CARDIOVERSION | Xyra, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12605371-B2 | Combination therapy for cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724602-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING BLOOD CLOTS IN BIOLOGICAL SAMPLES | 10X Genomics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | claimed |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | EPIZON PHARMA INC (US) | 2026-03-26 | — | — | US | claimed |
| WO-2006103206-A2 | COMBINATIONS COMPRISING AT LEAST ONE DIRECT THROMBIN INHIBITOR FOR THE TREATMENT OF THROMBOSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | WO | claimed |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | US | claimed |
| WO-2006067096-A1 | FILM CONTAINER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | claimed |
| US-20060131204-A1 | Film container | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-22 | — | — | US | claimed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| EP-1622621-A2 | USE OF DIPYRIDAMOLE OR MOPIDAMOLE FOR TREATMENT AND PREVENTION OF THROMBO-EMBOLIC DISEASES AND DISORDERS CAUSED BY EXCESSIVE FORMATION OF THROMBIN AND/OR BY ELEVATED EXPRESSION OF THROMBIN RECEPTORS | Boehringer Ingelheim International GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| US-20050014770-A1 | Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| WO-2004093881-A2 | USE OF DIPYRIDAMOLE OR MOPIDAMOLE FOR TREATMENT AND PREVENTION OF THROMBO-EMBOLIC DISEASES AND DISORDERS CAUSED BY EXCESSIVE FORMATION OF THROMBIN AND/OR BY ELEVATED EXPRESSION OF THROMBIN RECEPTORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-04 | — | — | WO | claimed |
| EP-0966454-B1 | DISUBSTITUTED BICYCLIC HETEROCYCLES, THEIR PRODUCTION AND USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-05-07 | — | — | EP | claimed |
| US-6087380-A | ANTITHROMBOTIC BENZIMIDAZOLES; ANTICOAGULANTS; 2-(N-(4-AMIDINOPHENYL)-AMINOMETHYL)-BENZIMIDAZOL-5-YL-CARBOXYLIC ACIDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-07-11 | — | — | US | claimed |